{
  "id": "mhgap#risk_safety_92214031",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "on antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up in the maintenance phase) (196); and Schneider- to six months. 90 3. Recommendations y There is a moderate-to-large increase of adverse y Polytherapy should be avoided as a treatment effects (discontinuation due to adverse effects) option when commencing maintenance therapy. depending on the medicine used. Research gaps y The certainty of evidence was moderate for the outcome recurrence. The certainty of evidence was y There is limited evidence on how long antipsychotic very low to low for the outcome adverse effects. medicine or mood stabilizers should be continued after remission for first episode bipolar disorder. Remarks y Most of the evidence is from HICs. Further research is y This recommendation refers to people living needed in LMICs. with bipolar disorder in the maintenance phase, Implementation considerations characterized by the absence of acute symptoms. y The use of lithium should be considered as first-line y People living with bipolar disorder should be of treatment for bipolar disorder only if clinical and involved in medicine choice in a supported laboratory monitoring are available and should decision-making process. only be prescribed under mental health specialist y Treatment with antipsychotic medicines or mood supervision. If laboratory examinations are not stabilizers should be combined with psychosocial available or feasible, lithium should be avoided and interventions (see other recommendations in other mood stabilizers or antipsychotics should this module). be considered. Do not prescribe lithium where the y Acquisition costs can differ substantially and also lithium supply may be frequently interrupted due to throughout the world. Recent antipsychotics may increased risk of relapse. Clinicians should conduct have higher costs than older antipsychotics. kidney and thyroid function, complete blood count, y Discontinuities in medicine availability (common electrocardiogram (ECG) and pregnancy tests before in LMICs) may interfere with the continuation beginning treatment where possible. of treatment. y Sodium valproate should not be used in women y Lithium carbonate, carbamazepine and quetiapine and girls of childbearing potential because of the (therapeutic alternatives: aripiprazole, olanzapine, high risk of birth defects and neurodevelopmental paliperidone) are available in the WHO EML (13). disorders in children exposed to sodium valproate in utero (see recommendation PSY8.2). 91",
  "gloss_vi": "On antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. most data were available for a follow-up of up in the maintenance phase) (196); and sch...",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "referral",
      "psychoeducation",
      "do_not_do",
      "management"
    ],
    "life_topics": [
      "study"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn on antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up in the maintenance phase) (196); and Schneider- to six months. 90 3. Recommendations y There is a moderate-to-large increase of adverse y Polytherapy should be avoided as a treatment effects (discontinuation due to adverse effects) option when commencing maintenance therapy. depending on the medicine used. Research gaps y The certainty of evidence was moderate for the outcome recurrence. The certainty of evidence was y There is limited evidence on how long antipsychotic very low to low for the outcome adverse effects. medicine or mood stabilizers should be continued after remission for first episode bipolar disorder. Remarks y Most of the evidence is from HICs. Further research is y This recommendation refers to people living needed in LMICs. with bipolar disorder in the maintenance phase, Implementation considerations characterized by the absence of acute symptoms. y The use of lithium should be considered as first-line y People living with bipolar disorder should be of treatment for bipolar disorder only if clinical and involved in medicine choice in a supported laboratory monitoring are available and should decision-making process. only be prescribed under mental health specialist y Treatment with antipsychotic medicines or mood supervision. If laboratory examinations are not stabilizers should be combined with psychosocial available or feasible, lithium should be avoided and interventions (see other recommendations in other mood stabilizers or antipsychotics should this module). be considered. Do not prescribe lithium where the y Acquisition costs can differ substantially and also lithium supply may be frequently interrupted due to throughout the world. Recent antipsychotics may increased risk of relapse. Clinicians should conduct have higher costs than older antipsychotics. kidney and thyroid function, complete blood count, y Discontinuities in medicine availability (common electrocardiogram (ECG) and pregnancy tests before in LMICs) may interfere with the continuation beginning treatment where possible. of treatment. y Sodium valproate should not be used in women y Lithium carbonate, carbamazepine and quetiapine and girls of childbearing potential because of the (therapeutic alternatives: aripiprazole, olanzapine, high risk of birth defects and neurodevelopmental paliperidone) are available in the WHO EML (13). disorders in children exposed to sodium valproate in utero (see recommendation PSY8.2). 91 On antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. most data were available for a follow-up of up in the maintenance phase) (196); and sch..."
}